AGP Executive Report
Last update: 7 hours agoCancer Care & Trials: Real-world data from the 2026 Kidney Cancer Research Summit suggests TKI-based regimens may deliver better disease control and durability in metastatic translocation RCC than non-TKI approaches. Rare Kidney Disease Pipeline: Akebia dosed the first patient in a Phase 2 basket trial of ebribafusp for complement-mediated kidney disorders, with initial results expected in 2027. Autoimmune Innovation: Evaxion says it has begun applying its AI-Immunology™ platform to autoimmune diseases, with experimental updates planned for PEGS Europe in November. Policy & Access: Kentucky is pushing to loosen state rules that block a new federal GLP-1 access program for Medicaid patients. Public Health & Safety: Russia tightened border Ebola screening, hospitalizing arrivals with symptoms. Health Systems & Costs: Opinion pieces highlight how insurance design can keep patients powerless, and another story warns that where you get an MRI can sharply change Medicare out-of-pocket costs. Mental Health: Coverage also points to the mental-health toll of working remotely in isolation and spotlights community efforts to support men’s suicide prevention. Healthcare Governance: SA Health reprimanded an employee for inappropriately accessing Tony Modra’s medical records.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
